2025 年第一次临时股东大会会议资料 股票简称：国邦医药 股票代码：605507 国邦医药集团股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年十一月 | | | 2025 年第一次临时股东大会会议资料 国邦医药集团股份有限公司 2025 年第一次临时股东大会会议议程 召开时间：2025 年 11 月 6 日（星期四） 14:00 召开地点：浙江省杭州市钱江世纪城民和路 886 号朝龙汇大厦 1 号楼 35 楼 召集人：董事会 主持人：董事长邱家军先生 会议议程： 一、主持人宣布会议开始； 二、介绍会议议程及会议须知； 三、报告现场出席的股东及股东代理人人数及其代表的有表决权股份数量； 四、介绍到会董事、监事、高级管理人员及列席会议的见证律师以及其他 人员； 五、推选本次会议计票人、监票人； 六、与会股东逐项审议以下议案 1、审议《关于公司取消监事会并修改<公司章程>的议案》； 2、审议《关于修订、制定部分公司内部制度的议案》； 3、审议《关于公司董事会换届暨选举第三届董事会非独立董事的议案》； 4、审议《关于公司董事会换届暨选举第三届董事会独立董事的议案》； 七、股东发言及公司董事、监事、 ...

Group 1: Macro Economic Overview - The Q3 economic slowdown aligns with expectations, with GDP growth at 4.8% year-on-year, matching consensus forecasts, and a quarter-on-quarter increase of 1.1% [3][4] - The second industry has weakened significantly, particularly in the construction sector, which is expected to show a notable decline in GDP [3][4] - Exports have rebounded, boosting industrial production, while the service sector remains resilient, with industrial added value increasing by 1.3% year-on-year in September [3][4] Group 2: Real Estate Market Analysis - New housing transactions have weakened, with a significant year-on-year decline in sales volume observed in major cities, indicating a challenging market environment [11][13] - The average transaction area of new homes in 30 major cities fell by 3% compared to the previous two weeks, with year-on-year declines of 32% and 28% compared to 2023 and 2024, respectively [13][34] - Second-hand housing prices have also shown a downward trend, with a year-on-year decline of 5.2%, although the rate of decline has narrowed compared to previous months [33][37] Group 3: Fixed Income and Fiscal Policy - National public budget revenue increased by 0.5% year-on-year in the first nine months of 2025, while expenditure grew by 3.1% [16][17] - The central government allocated 500 billion yuan to local governments from debt limits, indicating a proactive fiscal policy approach [16][18] - Tax revenue has shown steady growth, with a notable increase in securities transaction stamp duty revenue, which rose by 342.4% year-on-year [17][19] Group 4: Industry-Specific Insights - The electric vehicle and battery management sectors are experiencing growth, with companies like Huazhi Jie expanding into new application areas such as new energy vehicles and drones [22][24] - The coal industry is witnessing a price surge, with thermal coal prices nearing 750 yuan per ton, driven by seasonal demand and supply constraints [44][45] - The pharmaceutical sector, represented by Guobang Pharmaceutical, is showing steady growth in performance and profitability, indicating a robust market position [47]

Investment Rating - The report maintains a "Buy" rating for Guobang Pharmaceutical (605507) with a target price of —— yuan over the next six months [1]. Core Insights - The company's profit growth rate has significantly improved in the third quarter, indicating a recovery in profitability. Despite a slight decline in revenue, the net profit for Q3 increased by 23.17% year-on-year, showcasing enhanced profitability driven by improved gross margins and effective cost control [7]. - The growth in performance is primarily driven by the animal health raw materials business, which is entering a favorable cycle. The core product, Florfenicol, has seen a recovery in profitability due to industry capacity reduction, with shipments exceeding 2,000 tons in the first half of the year [7]. - The company's global market presence and high-value product strategy are enhancing its competitive edge, with products sold in 117 countries and regions, and partnerships established with over 5,000 clients and suppliers [7]. Financial Summary - For the first three quarters of 2025, the company achieved revenue of 4.47 billion yuan, a year-on-year increase of 1.17%, and a net profit of 670 million yuan, up 15.78% year-on-year. In Q3 alone, revenue was 1.44 billion yuan, down 5.39% year-on-year, while net profit rose by 23.17% [7]. - The forecast for 2025-2027 indicates an EPS of 1.88 yuan, 2.23 yuan, and 2.52 yuan respectively, with corresponding dynamic PE ratios of 12, 10, and 9 times [8].

Core Viewpoint - Guobang Pharmaceutical maintains good profit growth in Q3 2025, with a continuous improvement in profitability, driven by multiple core products receiving international certifications and a decrease in expense ratio [1] Financial Performance - In the first three quarters, the net profit attributable to the parent company reached 670 million yuan, representing a year-on-year increase of 15.78% - In Q3 alone, the net profit attributable to the parent company was 215 million yuan, showing a growth of 23.17% [1] Product Certifications - As of H1 2025, the company has achieved several key product certifications: - Doxycycline hydrochloride received the CEP certificate - Azithromycin, Telithromycin, and seven other products received FDA certification in the U.S. - Telithromycin successfully passed EU GMP and entered the Canadian market, marking a significant entry into mainstream markets in Europe and North America [1] Market Strategy and Outlook - The company continues to strengthen its global market channel platform advantage, utilizing a multi-product concentration strategy among customers - With the upward turning point in the animal health raw materials segment, the company maintains its profit forecast, projecting net profits attributable to the parent company of 995 million yuan, 1.235 billion yuan, and 1.391 billion yuan for 2025-2027 [1] Valuation - The current stock price corresponds to a PE ratio of 12.6, 10.2, and 9.0 times for the years 2025, 2026, and 2027 respectively, indicating a high valuation cost-effectiveness - The company maintains a "buy" rating based on these metrics [1]

医药生物/化学制药 国邦医药（605507.SH） 2025Q3 业绩稳健增长，盈利能力持续提升 2025 年 10 月 20 日 余汝意（分析师） 阮帅（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 ruanshuai@kysec.cn 证书编号：S0790524040007 2025Q3 利润端维持较好增长，盈利能力持续提升 投资评级：买入（维持） | 日期 | 2025/10/17 | | --- | --- | | 当前股价(元) | 22.47 | | 一年最高最低(元) | 25.10/18.53 | | 总市值(亿元) | 125.57 | | 流通市值(亿元) | 67.80 | | 总股本(亿股) | 5.59 | | 流通股本(亿股) | 3.02 | | 近 3 个月换手率(%) | 130.01 | 股价走势图 -20% -10% 0% 10% 20% 30% 2024-10 2025-02 2025-06 国邦医药 沪深300 数据来源：聚源 相关研究报告 《2025Q2 业绩超预期，动保板块迎来 大 幅 增 长 — 公 司 信 息 更 新 报 告 ...

Group 1 - The core viewpoint of the report is that Guobang Pharmaceutical (605507.SH) is rated as "Buy" due to its accelerating profit growth and improved profitability in Q3 [1] - The market share of its animal health products continues to increase, supported by the introduction of Zhejiang state-owned capital to drive strategic development [1] - The company is actively repurchasing shares, demonstrating confidence in its future growth [1] Group 2 - The report highlights the risks associated with industry policy changes, intensified market competition, potential product price declines, and foreign exchange rate fluctuations [1]

Core Insights - A total of 13 companies released their Q3 2025 financial reports on October 17, with 10 companies reporting year-on-year profit growth and 11 companies showing revenue growth [1] Company Performance Summary - **仕佳光子**: Reported earnings per share of 0.6631, net profit of 29,971.78 million, a year-on-year increase of 727.74%, and revenue of 156,043.74 million, up 113.96% [1] - **华东数控**: Earnings per share of 0.0800, net profit of 2,312.18 million, a year-on-year increase of 151.78%, but revenue decreased by 3.21% to 24,883.19 million [1] - ***ST聆达**: Reported a loss with earnings per share of -0.4780, net loss of 12,791.70 million, but revenue increased by 83.47% to 8,909.23 million [1] - **藏格矿业**: Earnings per share of 1.7566, net profit of 275,080.14 million, a year-on-year increase of 47.26%, and revenue of 240,144.68 million, up 3.35% [1] - **春风动力**: Earnings per share of 9.2900, net profit of 141,536.95 million, a year-on-year increase of 30.89%, and revenue of 1,489,633.24 million, up 30.10% [1] - **福耀玻璃**: Earnings per share of 2.7100, net profit of 706,385.42 million, a year-on-year increase of 28.93%, and revenue of 3,330,190.79 million, up 17.62% [1] - **民士达**: Earnings per share of 0.6200, net profit of 9,117.17 million, a year-on-year increase of 28.88%, and revenue of 34,335.35 million, up 21.77% [1] - **天安新材**: Earnings per share of 0.3240, net profit of 9,753.97 million, a year-on-year increase of 21.47%, and revenue of 227,340.62 million, up 3.47% [1] - **国邦医药**: Earnings per share of 1.2100, net profit of 67,024.26 million, a year-on-year increase of 15.78%, and revenue of 446,988.44 million, up 1.17% [1] - **佛燃能源**: Earnings per share of 0.3200, net profit of 49,030.67 million, a year-on-year increase of 6.07%, and revenue of 2,350,147.41 million, up 5.38% [1] - **康华生物**: Earnings per share of 1.4553, net profit of 18,911.07 million, a year-on-year decrease of 53.41%, and revenue decreased by 20.78% to 84,006.26 million [1] - **茂硕电源**: Reported a loss with earnings per share of -0.1624, net loss of 5,792.09 million, and revenue increased by 2.95% to 94,519.57 million [1] - **博世科**: Reported a loss with earnings per share of -0.4000, net loss of 21,224.60 million, but revenue increased by 27.10% to 151,235.47 million [1]

Policy Developments - The National Healthcare Security Administration (NHSA) announced that by the end of 2025, all coordinated areas in the country must implement instant settlement for medical insurance funds [2] - By the end of 2026, instant settlement funds should account for over 80% of the local medical insurance fund's monthly settlement funds, covering various medical expenses [2] Industry Developments - Jiangxi Province is promoting the development of modern seed industry for traditional Chinese medicine, focusing on the protection of medicinal material resources and the establishment of breeding bases [3] - The company Jiuzhoutong received approval for the market launch of the chemical raw material drug, Glycopyrrolate, which will enhance its product line and market competitiveness [5] - Sichuan Shuangma's subsidiary obtained approval for the chemical raw material drug, Leuprolide Acetate, further strengthening its competitive advantage in the domestic raw material drug sector [6] Financial Reports - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue [8] Investment Activities - OxTium Technology completed several million yuan in angel+ round financing, led by Sequoia China Seed Fund [11] Clinical Research - Eli Lilly announced positive results from two Phase 3 clinical trials for orforglipron, showing significant improvements in blood sugar control and weight loss for type 2 diabetes patients [14] Shareholder Actions - Kangtai Medical announced that major shareholder Wang Guili reduced her holdings by 4.24 million shares, decreasing her ownership to 8.95% [17]

Group 1 - Junshi Biosciences' JS207 received FDA approval for a Phase II/III clinical trial targeting neoadjuvant treatment in resectable, driver gene-negative non-small cell lung cancer patients, enhancing its international expansion and market potential [1] Group 2 - Eli Lilly's oral GLP-1 drug orforglipron demonstrated significant efficacy in two Phase III trials, achieving primary and all key secondary endpoints, including notable reductions in HbA1c, weight loss, and improvements in cardiovascular risk factors, reinforcing its competitive position in the GLP-1 market [2] Group 3 - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue, attributed to improved sales collection and optimized procurement payments, showcasing strong profitability resilience [3] Group 4 - Zhijiang Biopharmaceutical announced a share buyback plan of 60 million to 120 million yuan to support employee stock ownership plans or equity incentives, reflecting confidence in long-term development and aiming to strengthen core team commitment [4]

Core Insights - Multiple companies listed on the Shanghai Stock Exchange, including Tianan New Materials and Guobang Pharmaceutical, reported significant growth in their Q3 2025 performance, indicating a positive trend in the market [1][2] Group 1: Company Performance - Tianan New Materials reported a 3.5% increase in revenue and a 21.5% increase in net profit for the first three quarters, with Q3 net profit growing by 31% due to strong sales in automotive interior materials and building fireproof materials [1] - Guobang Pharmaceutical's revenue and net profit increased by 1.17% and 15.78% respectively in the first three quarters, with a notable 23.17% growth in Q3 alone [1] - Xiaoshangpin City, another company, achieved a 48.45% increase in performance for the first three quarters, significantly higher than the 16.78% growth in the first half of the year, with Q3 showing a remarkable 100.52% increase [2] Group 2: Market Trends - As of the morning of October 16, 43 companies in the Shanghai market had either forecasted or reported their Q3 performance, with 39 of them showing year-on-year growth in net profit [1] - Among the 39 companies, 21 exceeded their mid-year performance growth rates, indicating a robust recovery and growth trend in the market [1]